Impact of 18F-FDG PET on the Management in Patients With Recurrent Gynecologic cancer
暂无分享,去创建一个
[1] Lifeng Yang,et al. Meta-analysis of the diagnostic value of 18F-FDG PET/CT in the recurrence of epithelial ovarian cancer , 2022, Frontiers in Oncology.
[2] P. Tamayo,et al. 18F-FDG PET/CT in ovarian cancer recurrence: Clinical impact, correlation with ceCT and CA-125, and prognostic value. , 2020, Revista espanola de medicina nuclear e imagen molecular.
[3] M. Beckmann,et al. Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019). , 2019, Geburtshilfe und Frauenheilkunde.
[4] Xiaoliang Liu,et al. The clinical value of PET and PET/CT in the diagnosis and management of suspected cervical cancer recurrence , 2017, Nuclear medicine communications.
[5] A. Sahdev,et al. The role of 18F-FDG PET CT in common gynaecological malignancies , 2017, The British journal of radiology.
[6] S. Kim,et al. Clinical usefulness of post-treatment FDG PET/CT in patients with ovarian malignancy , 2016, Annals of Nuclear Medicine.
[7] H. Salvesen,et al. High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature , 2016, The Journal of Nuclear Medicine.
[8] M. Munsell,et al. Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary. , 2014, Gynecologic oncology.
[9] M. Kaneuchi,et al. Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[10] Ai Zheng,et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis , 2014, Nuclear medicine communications.
[11] E. Brun,et al. Clinical Impact of 2-Deoxy-2-[18F]fluoro-D-Glucose (FDG)–Positron Emission Tomography (PET) on Treatment Choice in Recurrent Cancer of the Cervix Uteri , 2013, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[12] A. Bhattacharya,et al. Role of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of recurrence in patients with cervical cancer , 2013, Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India.
[13] R. Coleman,et al. Impact of 18F-FDG PET Used After Initial Treatment of Cancer: Comparison of the National Oncologic PET Registry 2006 and 2009 Cohorts , 2012, The Journal of Nuclear Medicine.
[14] A. Bilici,et al. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management? , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[15] C. Bodet-Milin,et al. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[16] M. Fulham,et al. The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. , 2009, Gynecologic oncology.
[17] O. Hoekstra,et al. Clarifying the Diagnosis of Clinically Suspected Recurrence of Cervical Cancer: Impact of 18F-FDG PET , 2008, Journal of Nuclear Medicine.
[18] Yong-Man Kim,et al. Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma. , 2008, Gynecologic oncology.
[19] Barry A Siegel,et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] V. Bettinardi,et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[21] H. Chung,et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[22] H. Chung,et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. , 2007, Gynecologic oncology.
[23] M. Quinn,et al. The impact of PET/CT in the management of recurrent ovarian cancer. , 2006, Gynecologic oncology.
[24] T. Yen,et al. Restaging of recurrent cervical carcinoma with dual‐phase [18F]fluoro‐2‐deoxy‐D‐glucose positron emission tomography , 2004, Cancer.
[25] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[26] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[27] J. Tukey,et al. Transformations Related to the Angular and the Square Root , 1950 .
[28] M. Soussan,et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. , 2008, Gynecologic oncology.
[29] K. Sugimura,et al. Performance of integrated FDG–PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG–PET/non-contrast-enhanced CT and enhanced CT , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[30] Tao Jiang,et al. Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Noninvasively Characterizing the Different Αvβ3 Expression Patterns in Lung Cancers with Rgd-uspio Using a Clinical 3.0t Mr Scanner , 2022 .